McDermott advised Biocorp Production SA on its proposed acquisition by Novo Nordisk, while Novo Nordisk A/S was advised by Bird & Bird. Novo Nordisk A/S and...
You must be a Standard 1 Year member to access this content.
McDermott advised DiogenX in its fundraising. DiogenX, a biotechnology company specializing in the regeneration of beta cells that produce insulin for the treatment of diabetes, has...
You must be a Standard 1 Year member to access this content.
Goodwin advised Sofinnova Partners, Intermediate Capital Group, Tekla et CTI Life Sciences. Jones Day advised Amolyt Pharma. McDermott Will & Emery advised Andera Partners, Novo Holdings...
You must be a Standard 1 Year member to access this content.
McDermott Will & Emery advised Meiogenix on the round. Meiogenix announced the closing of a USD 13 million (EUR 11 million) Series A financing round led...
You must be a Standard 1 Year member to access this content.
McDermott Will & Emery advised Corteria Pharmaceuticals on the deal. Corteria Pharmaceuticals, a French biotechnology company specializing in the development of interceptive therapies for heart failure...
You must be a Standard 1 Year member to access this content.
IN BRIEF: McDermott Will & Emery, advised on the matter. McDermott Will & Emery advised Aglaia Therapeutics with a team including Anthony Paronneau (Picture – Corporate...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Sectoral Asset Management and Andera Partners on the deal. McDermott Will & Emery advised a syndicate of Amolyt Pharma’s historical investors, including LSP,...
You must be a Standard 1 Year member to access this content.
IN BRIEF: Bird & Bird, McDermott Will & Emery, Weil, Gotshal & Manges, advised on the matter. Bird & Bird advised Coave Therapeutics (Horama SAS) with...
You must be a Standard 1 Year member to access this content.
